Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

Eli Lilly's next-generation products look promising ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, including ...